Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study

Lancet Infectious Diseases
Nov 2020 Volume 20 Number 11 p1217-1348, e275-e297
http://www.thelancet.com/journals/laninf/issue/current

 

Articles
Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study
Maja Jahnmatz, and the BPZE1 study team